Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studies radiation dose from a lutetium-177 treatment in men with prostate cancer

Measures radiation dose delivered by lutetium-177 PSMA-617 to tumours in adults with prostate cancer.

Key facts

Who runs it
Institut Bergonié
Where
Bordeaux, FranceSee the site
Trial code
Registry title
Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Status
Recruiting
People taking part
50 people, planned
Started
1 Nov 2023
Expected to end
31 Dec 2027
Type of study
Observational
Record updated
30 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men aged 18 and over with advanced prostate cancer that has spread and no longer responds to hormone-lowering treatment. They have had, or are about to have, 177Lu-PSMA-617 treatment.

Age
18 years and over
Sex
Men only
Disease stage
Prostate cancer that is getting worse, has spread (metastatic), no longer responds to castration (castration-resistant), and has a lot of PSMA on its cells.
Earlier treatment
Taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide or abiraterone-prednisone). Treatment with 177Lu-PSMA-617 is planned, started or completed since 01/11/2023.
Biomarker or test result
The cancer overexpresses prostate specific membrane antigen (PSMA).

Main reasons for not taking part

  • Cannot lie still for 1 hour for image acquisition
  • Lives more than 2 hours' drive from the Institut Bergonié
  • Has expressed opposition to the use of his medical data for research

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patient aged 18 and over
  • Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01/11/2023:; Progressive, metastatic, castration-resistant prostate cancer,; overexpressing prostate specific membrane antigen (PSMA); treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone)
  • Patient able to lie still for 1 hour for image acquisition
  • Patient's place of residence < 2 hours' drive from the Institut Bergonié
  • Patient has not expressed any opposition to the use of his/her medical data for research purposes

Who cannot take part

  • None

Where in France

  • Institut BergonieBordeaux, FranceContact: Nadège ANIZANTaking people

About the trial

What the trial wants to find out

Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Optimisation and Safety of an Innovative Nuclear Medicine Treatment: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Plain-language title
Studies radiation dose from a lutetium-177 treatment in men with prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 January 2026